In:
Medicine, Ovid Technologies (Wolters Kluwer Health), Vol. 102, No. 13 ( 2023-03-31), p. e33373-
Abstract:
This study aimed to explore the effects of recombinant human thrombopoietin (rhTPO) on platelet recovery in decitabine, cytarabine, aclarubicin, and G-CSF (DCAG)-treated patients with intermediate-high-risk myelodysplastic syndrome/hypo proliferative acute myeloid leukemia. Methods: Recruited patients were at a ratio of 1:1 into 2 groups: the rhTPO group (DCAG + rhTPO) and control group (DCAG). The primary endpoint was the time for platelets to recover to ≥ 20 × 10 9 /L. The secondary endpoints were the time for platelets to recover to ≥ 30 × 10 9 /L and ≥ 50 × 10 9 /L, overall survival (OS), and progression-free survival (PFS). Results: The time required for platelet recovery to ≥ 20 × 10 9 /L, ≥30 × 10 9 /L, and ≥ 50 × 10 9 /L in the rhTPO group was significantly shorter (6.5 ± 2.2 vs 8.4 ± 3.1 days, 9.0 ± 2.7 vs 12.2 ± 3.9 days, 12.4 ± 4.7 vs 15.5 ± 9.3 days, respectively; all P 〈 .05 vs controls). The amount of platelet transfusion in the rhTPO group was smaller (4.4 ± 3.1 vs 6.1 ± 4.0 U, P = .047 vs controls). The bleeding score was lower ( P = .045 vs controls). The OS and PFS were significantly different ( P = .009 and P = .004). The multivariable analysis showed that age, karyotype, and time for PLT recovery to ≥ 20 × 10 9 /L were independently associated with OS. Adverse events were similar. Conclusions: This study suggests that rhTPO leads to a faster platelet recovery after DCAG treatment, reduces the risk of bleeding, reduces the number of platelet transfusions, and prolongs the OS and PFS.
Type of Medium:
Online Resource
ISSN:
0025-7974
DOI:
10.1097/MD.0000000000033373
Language:
English
Publisher:
Ovid Technologies (Wolters Kluwer Health)
Publication Date:
2023
detail.hit.zdb_id:
2049818-4
Permalink